Dec 12 (Reuters) - GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory ...

In a new study, adults 45 and up who got this seasonal virus had a higher risk of major heart issues, especially in the first ...

There is underreporting of adverse effects from vaccines; but, in the vast majority of cases, the side effects from the ...

You are correct that there is underreporting of adverse effects from vaccines; however, in the vast majority of cases, the ...

You recently posted a couple of articles about the respiratory syncytial virus (RSV) vaccine and the benefits versus the ...

Investing.com -- GSK plc (LSE:GSK) announced Friday that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the indication of its RSV ...

U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective RSV treatments for infants would face fresh safety scrutiny following ...

By Dan Levine and Patrick Wingrove Dec 9 (Reuters) - U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective RSV treatments for ...

HIQA has launched a public consultation on its draft health technology assessment of immunisation against the Respiratory ...

A new study has found that a significant percentage of adults in the United States have at least one risk factor for severe respiratory syncytial virus (RSV), even as eligibility for the RSV ...

You recently posted a couple of articles about the respiratory syncytial virus (RSV) vaccine and the benefits versus ...

Federal health officials are reviewing the safety of two injectable drugs used to protect babies and toddlers from the RSV ...